All In Biotech

Drug Trial Radar · NCT07921966

Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants

A Phase 1, Open-Label, Two-Sequence, Five-Period, Single Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasal Olanzapine and Relative Bioavailability Compared to Olanzapine Intramuscular Injection in Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Oct 16, 2026

Primary completion

Jan 14, 2027

Study completion Jan 14, 2027

Sponsor

Lead sponsor
Neurelis, Inc.Industry
Sponsor type
Industry
First posted
Nov 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, 5-period, 2-sequence, single ascending dose study designed to assess the pharmacokinetics, dose proportionality, safety, and tolerability of NRL-1004 (olanzapine nasal spray), and to assess the relative bioavailability of NRL-1004, compared to olanzapine intramuscular injection (ZYPREXA IM), in healthy adult participants. The study will be conducted in a single clinical research unit (CRU).

Conditions

  • Healthy Adult Participants

Interventions

  • NRL-1004 2.5 mgDrug

    Olanzapine nasal spray

  • ZYPREXA IM 10mgDrug

    Olanzapine IM injection

  • NRL-1004 5.0 mgDrug

    Olanzapine nasal spray

  • NRL-1004 7.5 mgDrug

    Olanzapine nasal spray

  • NRL-1004 10.0 mgDrug

    Olanzapine nasal spray

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
  2. Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
  3. Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
  4. Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
  5. Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
  6. Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
  7. Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
  8. Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
  9. Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
  10. Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
  11. Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.